Tolerogenic dendritic cells inhibit antiphospholipid syndrome derived effector/memory CD4 + T cell response to β2GPI

Annals of the Rheumatic Diseases

Volumn 71, Issue 1, 2012, Pages 120-128

  Torres Aguilar, Honorio ^a,b,c   Blank, Miri ^a,b   Kivity, Shaye ^a,b,c   Misgav, Mudi ^a   Luboshitz, Jacob ^a   Pierangeli, Silvia S ^d   Shoenfeld, Yehuda ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c National Center of Blood Transfusion   (Mexico)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ANTIGEN PRESENTING CELL; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; EFFECTOR CELL; FEASIBILITY STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MEMORY CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REGULATORY T LYMPHOCYTE; TOLEROGENIC DENDRITIC CELL;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED;

EID: 82955216237     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200063     Document Type: Article

References (36)

1. Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986;13:486-9.
2. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27. (Pubitemid 34303815)
3. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7. (Pubitemid 20189625)
4. Blank M, Cohen J, Toder V, et al. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA 1991;88:3069-73. (Pubitemid 21916560)
5. Gharavi AE, Pierangeli SS, Espinola RG, et al. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 2002;46:545-52. (Pubitemid 34136593)
6. Pierangeli SS, Blank M, Liu X, et al. A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo. J Autoimmun 2004;22:217-25. (Pubitemid 38372192)
7. Ioannou Y, Romay-Penabad Z, Pericleous C, et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost 2009;7:833-42.
8. De Laat B, Derksen RH, Reber G, et al. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. J Thromb Haemost 2011;9:149-53.
9. Blank M, Shoenfeld Y, Cabilly S, et al. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 1999;96:5164-8. (Pubitemid 29214553)
10. Tomer Y, Blank M, Shoenfeld Y. Suppression of experimental antiphospholipid syndrome and systemic lupus erythematosus in mice by anti-CD4 monoclonal antibodies. Arthritis Rheum 1994;37:1236-44. (Pubitemid 24313326)
11. Blank M, Krause I, Buskila D, et al. Bromocriptine immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of nonspecific T suppressor cells. Cell Immunol 1995;162:114-22.
12. Blank M, George J, Barak V, et al. Oral tolerance to low dose beta 2-glycoprotein I: immunomodulation of experimental antiphospholipid syndrome. J Immunol 1998;161:5303-12. (Pubitemid 28519090)
13. Krause I, Blank M, Sherer Y, et al. Induction of oral tolerance in experimental antiphospholipid syndrome by feeding with polyclonal immunoglobulins. Eur J Immunol 2002;32:3414-24. (Pubitemid 36024379)
14. Blank M, Krause I, Lanir N, et al. Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation. The importance of the T cell. Arthritis Rheum 1995;38:115-22.
15. Tolomeo T, Rico De Souza A, Roter E, et al. T cells demonstrate a Th1-biased response to native beta2-glycoprotein I in a murine model of anti-phospholipid antibody induction. Autoimmunity 2009;42:292-5.
16. Hattori N, Kuwana M, Kaburaki J, et al. T cells that are autoreactive to beta2- glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum 2000;43:65-75. (Pubitemid 30368214)
17. Arai T, Yoshida K, Kaburaki J, et al. Autoreactive CD4(+) T-cell clones to beta2- glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site. Blood 2001;98:1889-96.
18. Sebastiani GD, Galeazzi M, Morozzi G, et al. The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant. Semin Arthritis Rheum 1996;25:414-20. (Pubitemid 26197399)
19. Kuwana M. Beta2-glycoprotein I: antiphospholipid syndrome and T-cell reactivity. Thromb Res 2004;114:347-55. (Pubitemid 39422566)
20. Yoshida K, Arai T, Kaburaki J, et al. Restricted T-cell receptor beta-chain usage by T cells autoreactive to beta(2)-glycoprotein I in patients with antiphospholipid syndrome. Blood 2002;99:2499-504. (Pubitemid 34525437)
21. Kuwana M. Autoreactive CD4(+) T cells to beta(2)-glycoprotein I in patients with antiphospholipid syndrome. Autoimmun Rev 2003;2:192-8. (Pubitemid 36793942)
22. Miller SD, Turley DM, Podojil JR. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol 2007;7:665-77. (Pubitemid 47327394)
23. Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 2010;108:111-65.
24. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685-711. (Pubitemid 37174545)
25. Torres-Aguilar H, Blank M, Jara LJ, et al. Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity. Autoimmun Rev 2010;10:8-17.
26. Lakkis FG, Sayegh MH. Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol 2003;14:2402-10. (Pubitemid 37052389)
27. Torres-Aguilar H, Aguilar-Ruiz SR, González-Pérez G, et al. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigenspecifi c anergy and regulatory properties in memory CD4+ T cells. J Immunol 2010;184:1765-75.
28. Torres-Aguilar H, Sánchez-Torres C, Jara LJ, et al. IL-10/TGF-beta-treated dendritic cells, pulsed with insulin, specifically reduce the response to insulin of CD4+ effector/memory T cells from type 1 diabetic individuals. J Clin Immunol 2010;30:659-68.
29. Dalai SK, Mirshahidi S, Morrot A, et al. Anergy in memory CD4+ T cells is induced by B cells. J Immunol 2008;181:3221-31.
30. Anderson AE, Sayers BL, Haniffa MA, et al. Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells. J Leukoc Biol 2008;84:124-33. (Pubitemid 351960287)
31. Kalinski P. Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4. Curr Opin Investig Drugs 2009;10:526-35.
32. Pinzon-Charry A, Maxwell T, López JA. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 2005;83:451-61. (Pubitemid 41805745)
33. Bennaceur K, Chapman J, Brikci-Nigassa L, et al. Dendritic cells dysfunction in tumour environment. Cancer Lett 2008;272:186-96.
34. Bogunovic D, Manches O, Godefroy E, et al. TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res 2011;71:5467-76.
35. Huang FP, Chen YX, To CK. Guiding the "misguided" - functional conditioning of dendritic cells for the DC-based immunotherapy against tumours. Eur J Immunol 2011;41:18-25.
36. Pajtasz-Piasecka E, Indrová M. Dendritic cell-based vaccines for the therapy of experimental tumors. Immunotherapy 2010;2:257-68.